ALKS 5461 accepted for review following previous refusal-to-file for depression: industry news round-up

In this week’s industry news round-up, we’ve chosen the latest updates from a wide range of disorders extending from depression to multiple sclerosis. Find out more about our selection of the highlights below. Our pick of the headlines include: ALKS 5461 accepted for review following previous refusal-to-file for depression Aimovig® halves migraine days in late-stage study, heading towards possible May approval Biogen and Ionis in 10-year collaboration to develop novel drug candidates for neurological diseases Novartis to seek FDA approval after additional Phase III data for siponimod in SPMS announced ALKS 5461 accepted for review following previous refusal-to-file for depression...